Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sensitivity and Specificity of Chimerism Tests in Predicting Leukemia Relapse Using Increasing Mixed Chimerism.
Zhang R, Shang Y, Cioccio J, Rakszawski K, Nickolich M, Ehmann C, Inoue Y, Naik S, Rybka W, Zheng H, Mierski J, Silar B, Liao J, Greiner R, Brown V, Claxton D, Ning J, Zhou S, Mineishi S, Minagawa K, Shike H. Zhang R, et al. Among authors: silar b. J Mol Diagn. 2024 Dec;26(12):1159-1170. doi: 10.1016/j.jmoldx.2024.09.003. J Mol Diagn. 2024. PMID: 39603755
Recurrent disease after a matched sibling hematopoietic transplant in an aplastic anemia patient with a disease risk allele, HLA-B*40:02.
Khosla A, Inoue Y, Cioccio J, Rakszawski K, Songdej N, Nickolich M, Zheng H, Naik S, Ehmann C, Claxton D, Rybka W, Sivik J, Mierski J, Silar B, Vajdic C, Hohl R, Shike H, Mineishi S, Minagawa K. Khosla A, et al. Among authors: silar b. Blood Transfus. 2024 Nov;22(6):525-528. doi: 10.2450/BloodTransfus.674. Epub 2024 Aug 26. Blood Transfus. 2024. PMID: 39447189 Free PMC article. No abstract available.
Impact of post-transplant cyclophosphamide and splenomegaly on primary graft failure and multi-lineage cytopenia after allogeneic hematopoietic cell transplantation.
Zulch E, Inoue Y, Cioccio J, Rakszawski K, Songdej N, Nickolich M, Zheng H, Naik S, Rybka W, Ehmann C, Sivik J, Mierski J, Silar B, Vajdic C, Greiner R, Brown V, Hohl R, Claxton D, Shike H, Paules CI, Mineishi S, Minagawa K. Zulch E, et al. Among authors: silar b. Leuk Res. 2024 Aug;143:107530. doi: 10.1016/j.leukres.2024.107530. Epub 2024 Jun 3. Leuk Res. 2024. PMID: 38852515
Donor HLA mismatch promotes full donor T-cell chimerism in the allogeneic stem cell transplant with reduced-intensity conditioning and post-transplant cyclophosphamide GVHD prophylaxis.
Cioccio J, Rakszawski K, Zheng H, Nickolich M, Naik S, Wirk B, Rybka W, Ehmann C, Silar B, Vajdic C, Shah N, Tuanquin L, Greiner R, Brown V, Hohl R, Claxton D, Mineishi S, Minagawa K, Shike H. Cioccio J, et al. Among authors: silar b. Ann Hematol. 2023 Mar;102(3):613-620. doi: 10.1007/s00277-022-05077-2. Epub 2022 Dec 17. Ann Hematol. 2023. PMID: 36527460
Low-dose total body irradiation promotes T-cells donor chimerism in reduced-intensity/non-myeloablative allogeneic stem cell transplant with post-transplant cyclophosphamide.
Shah N, Cioccio J, Rakszawski K, Zheng H, Nickolich M, Naik S, Wirk B, Rybka W, Ehmann C, Silar B, Vajdic C, Mierski J, Zhou S, Shike H, Greiner R, Brown V, Hohl R, Claxton D, Mineishi S, Minagawa K, Tuanquin L. Shah N, et al. Among authors: silar b. Leuk Res. 2022 Dec;123:106969. doi: 10.1016/j.leukres.2022.106969. Epub 2022 Oct 22. Leuk Res. 2022. PMID: 36306723 No abstract available.
Non-myeloablative allogeneic stem cell transplant with fludarabine and reduced dose cyclophosphamide in acute myeloid leukemia for older adults with comorbidities.
Pizzola CJ, Cioccio J, Rakszawski KL, Nickolich M, Ehmann WC, Rybka WB, Wirk B, Naik S, Zheng H, Silar B, Shike H, Zhou S, Mineishi S, Minagawa K, Claxton DF. Pizzola CJ, et al. Among authors: silar b. Bone Marrow Transplant. 2022 Nov;57(11):1743-1745. doi: 10.1038/s41409-022-01821-4. Epub 2022 Sep 12. Bone Marrow Transplant. 2022. PMID: 36097041 No abstract available.
Improved outcome in AML relapse after allogeneic transplant with high-intensity chemotherapy followed by 2nd allogeneic stem cell transplant or donor lymphocyte infusion.
Shah N, Rakszawski K, Nickolich M, Ehmann C, Wirk B, Naik S, Rybka W, Zheng H, Mierski J, Silar B, Mackey G, Greiner R, Brown V, Claxton D, Mineishi S, Minagawa K. Shah N, et al. Among authors: silar b. Ann Hematol. 2021 Oct;100(10):2585-2592. doi: 10.1007/s00277-021-04616-7. Epub 2021 Jul 29. Ann Hematol. 2021. PMID: 34322774